🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

13+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 13 of 13 recruiting trials for “Classic hairy cell leukemia”

Phase 1, PHASE2RecruitingNCT06965114 ↗

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

👨‍⚕️ Seema A Bhat, Ohio State University Comprehensive Cancer Center LAO📍 1 site📅 Started Jun 2026View details ↗
NARecruitingNCT06781515 ↗

Assessment of Disease Burden in Hairy Cell Leukemia

👨‍⚕️ Pier Luigi Zinzani, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 1 site📅 Started Jan 2025View details ↗
Phase 2RecruitingNCT06311227 ↗

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

👨‍⚕️ Robert J Kreitman, National Cancer Institute LAO📍 21 sites📅 Started Dec 2024View details ↗
RecruitingNCT06774677 ↗

Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management

👨‍⚕️ Lucia Catani, PhD, IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 3 sites📅 Started Dec 2024View details ↗
RecruitingNCT06764524 ↗

Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management

👨‍⚕️ Lucia Catani, PhD, IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 1 site📅 Started Dec 2024View details ↗
Phase 2RecruitingNCT06561360 ↗

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

👨‍⚕️ Jae Park, MD, Memorial Sloan Kettering Cancer Center📍 10 sites📅 Started Sep 2024View details ↗
Phase 1RecruitingNCT06340737 ↗

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

👨‍⚕️ Matthew Frank, MD, PhD, Stanford University📍 1 site📅 Started Mar 2024View details ↗
Phase 1RecruitingNCT04815356 ↗

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

👨‍⚕️ Robert J Kreitman, M.D., National Cancer Institute (NCI)📍 1 site📅 Started May 2022View details ↗
Phase 2RecruitingNCT04322383 ↗

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

👨‍⚕️ Robert J Kreitman, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Jan 2021View details ↗
Phase 2RecruitingNCT04324112 ↗

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

👨‍⚕️ Robert J Kreitman, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Oct 2020View details ↗
RecruitingNCT02560883 ↗

Hairy Cell Leukemia Patient Data Registry

👨‍⚕️ Michael Grever, MD, The Ohio State University Comprehensive Cancer Center📍 6 sites📅 Started Jan 2013View details ↗
Phase 2RecruitingNCT00412594 ↗

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

👨‍⚕️ Farhad Ravandi-Kashani, M.D. Anderson Cancer Center📍 1 site📅 Started Jun 2004View details ↗
Phase 2, PHASE3RecruitingNCT02131753 ↗

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

👨‍⚕️ Mathias J Rummel, Prof. Dr., Justus-Liebig-University | University Hospital | Medicinal Clinic IV📍 76 sites📅 Started May 2004View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →